At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 203 enrolled
Drug / intervention
BMS-986165 Dose A +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA)
In Brief
A Phase 2 clinical trial evaluating BMS-986165 Placebo, BMS-986165 Dose A, and 3 other interventions for Active Psoriatic Arthritis. Completed, enrolled 203 participants across 94 sites in 9 countries.
Detailed Summary
The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily \[QD\]) at Week 16 in the treatment of participants with active PsA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActive Psoriatic Arthritis
CountriesCzechia, Germany, Hungary, Italy, Poland, Russia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMar 2019
Enrollment StartApr 2019
Primary CompletionApr 2020
Study CompletionJan 2021
TodayJul 2026
First PostedMar 19, 2019
Enrollment StartApr 1, 2019
Primary CompletionApr 27, 2020
Study CompletionJan 27, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.3 years ago
Interventions
BMS-986165 Placeboother
Participants will receive BMS-986165 matching placebo QD
BMS-986165 Dose Adrug
Participants will receive BMS-986165 Dose A QD.
BMS-986165 Dose Bdrug
Participants will receive BMS-986165 dose B QD.
Ustekinumabdrug
Participants will receive ustekinumab SQ injection QD.
Ustekinumab Placeboother
Participants will receive ustekinumab SQ matching placebo QD